200 related articles for article (PubMed ID: 12068339)
41. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study.
Stockley RA; Chopra N; Rice L
Thorax; 2006 Feb; 61(2):122-8. PubMed ID: 16443706
[TBL] [Abstract][Full Text] [Related]
42. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
Murray J; Rosenthal R; Somerville L; Blake K; House K; Baitinger L; VanderMeer A; Dorinsky P
Ann Allergy Asthma Immunol; 2004 Oct; 93(4):351-9. PubMed ID: 15521371
[TBL] [Abstract][Full Text] [Related]
43. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
[TBL] [Abstract][Full Text] [Related]
44. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD.
O'Donnell DE; Sciurba F; Celli B; Mahler DA; Webb KA; Kalberg CJ; Knobil K
Chest; 2006 Sep; 130(3):647-56. PubMed ID: 16963658
[TBL] [Abstract][Full Text] [Related]
45. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
Pearlman DS; Stricker W; Weinstein S; Gross G; Chervinsky P; Woodring A; Prillaman B; Shah T
Ann Allergy Asthma Immunol; 1999 Mar; 82(3):257-65. PubMed ID: 10094216
[TBL] [Abstract][Full Text] [Related]
46. A randomized, placebo-controlled study to evaluate the role of salmeterol in the in-hospital management of asthma.
Peters JI; Shelledy DC; Jones AP; Lawson RW; Davis CP; LeGrand TS
Chest; 2000 Aug; 118(2):313-20. PubMed ID: 10936118
[TBL] [Abstract][Full Text] [Related]
47. Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility.
Perng DW; Wu CC; Su KC; Lee YC; Perng RP; Tao CW
Lung; 2006; 184(4):217-22. PubMed ID: 17006748
[TBL] [Abstract][Full Text] [Related]
48. A comparison of the efficacy of long-acting beta 2-agonists: eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics. Force Research Group.
Campbell LM; Anderson TJ; Parashchak MR; Burke CM; Watson SA; Turbitt ML
Respir Med; 1999 Apr; 93(4):236-44. PubMed ID: 10464887
[TBL] [Abstract][Full Text] [Related]
49. Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients.
Cazzola M; Mantero A; Santus P; Carlucci P; Mondoni M; Bosotti L; Centanni S
Pulm Pharmacol Ther; 2007; 20(3):258-64. PubMed ID: 16600647
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study.
Ulrik CS
Thorax; 1995 Jul; 50(7):750-4. PubMed ID: 7570409
[TBL] [Abstract][Full Text] [Related]
51. [Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial].
Fang LZ; Liang X; Zhang JQ; Liu L; Fu WP; Zhao ZH; Dai LM
Zhonghua Jie He He Hu Xi Za Zhi; 2008 Nov; 31(11):811-4. PubMed ID: 19080533
[TBL] [Abstract][Full Text] [Related]
52. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium.
van Noord JA; de Munck DR; Bantje TA; Hop WC; Akveld ML; Bommer AM
Eur Respir J; 2000 May; 15(5):878-85. PubMed ID: 10853852
[TBL] [Abstract][Full Text] [Related]
53. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.
Cazzola M; Andò F; Santus P; Ruggeri P; Di Marco F; Sanduzzi A; D'Amato M
Pulm Pharmacol Ther; 2007; 20(5):556-61. PubMed ID: 16914336
[TBL] [Abstract][Full Text] [Related]
54. Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. UK Study Group.
Boyd G
Eur Respir J; 1995 Sep; 8(9):1494-8. PubMed ID: 8575574
[TBL] [Abstract][Full Text] [Related]
55. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.
Rennard SI; Anderson W; ZuWallack R; Broughton J; Bailey W; Friedman M; Wisniewski M; Rickard K
Am J Respir Crit Care Med; 2001 Apr; 163(5):1087-92. PubMed ID: 11316640
[TBL] [Abstract][Full Text] [Related]
56. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
[TBL] [Abstract][Full Text] [Related]
57. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
Lindberg A; Szalai Z; Pullerits T; Radeczky E
Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
[TBL] [Abstract][Full Text] [Related]
58. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance.
Donohue JF; Hanania NA; Sciarappa KA; Goodwin E; Grogan DR; Baumgartner RA; Hanrahan JP
Ther Adv Respir Dis; 2008 Apr; 2(2):37-48. PubMed ID: 19124357
[TBL] [Abstract][Full Text] [Related]
59. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
Fabbri LM; Calverley PM; Izquierdo-Alonso JL; Bundschuh DS; Brose M; Martinez FJ; Rabe KF;
Lancet; 2009 Aug; 374(9691):695-703. PubMed ID: 19716961
[TBL] [Abstract][Full Text] [Related]
60. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
Hagedorn C; Kässner F; Banik N; Ntampakas P; Fielder K
Respir Med; 2013 Apr; 107(4):542-9. PubMed ID: 23337300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]